FDA Approvals, New Appointments, and Official Statements - Research Report on Pfizer, Aetna, Lilly, GSK, and Sanofi

FDA Approvals, New Appointments, and Official Statements - Research Report on
                    Pfizer, Aetna, Lilly, GSK, and Sanofi

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 27, 2013

NEW YORK, November 27, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Aetna Inc. (NYSE: AET), Eli Lilly & Co. (NYSE: LLY),
GlaxoSmithKline plc (ADR) (NYSE: GSK), and Sanofi SA (ADR) (NYSE: SNY).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On November 21, 2013, Pfizer Inc. (Pfizer) announced that the U.S. Food and
Drug Administration (FDA) has granted Pfizer's XALKORI (crizotinib) regular
approval for the treatment of patients with metastatic ALK-positive non-small
cell lung cancer (NSCLC) as detected by an FDA-approved test. According to the
Company, the FDA's approval marks the conversion of an accelerated approval to
a regular approval and is based on data from pivotal Phase 3 PROFILE 1007
confirmatory trial comparing XALKORI to standard chemotherapy in previously
treated patients. Garry Nicholson, President and General Manager, Pfizer
Oncology Business Unit, said, "XALKORI has dramatically changed the treatment
landscape for patients with advanced ALK-positive NSCLC. Achievement of this
milestone underscores Pfizer's commitment to provide physicians with effective
cancer therapies for their patients." The Full Research Report on Pfizer Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/d702_PFE

--

Aetna Inc. Research Report

On November 20, 2013, Aetna Inc. (Aetna) announced that it has named Yehong
Zhang, Ph.D., as General Manager, Greater China, effective immediately.
According to Aetna, Dr. Zhang will be responsible for the Company's growth in
China, Hong Kong, Macau, and Taiwan. Most recently, Dr. Zhang served as the
CEO of Simcere MSD Pharmaceutical Co. Ltd, a joint venture established in 2012
between Simcere and Merck & Co. The Full Research Report on Aetna Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/cbe9_AET

--

Eli Lilly & Co. Research Report

On November 19, 2013, Eli Lilly & Co. (Lilly) announced a statement from John
C. Lechleiter, Ph.D., Chairman and CEO of Lilly, regarding the Company's
investment of $7.5 million toward startup of the Indiana Biosciences Research
Institute. According to Dr. Lechleiter, "Each year in Indiana, billions of
dollars are invested in research and development to advance medical
innovation. This institute will help Indiana attract additional global talent
and will nurture partnerships across the state and across the country -
keeping more research dollars in Indiana and attracting more federal research
funds to our state." Dr. Lechleiter added, "In the last decade, Indiana has
come of age as a recognized leader in the life sciences - with demonstrated
capabilities in biopharmaceuticals, medical devices, and diagnostics, as well
as in the areas of animal health and crop sciences. The research institute
will fuel Indiana's economy and will underscore the state's position as a life
sciences leader. The bio-landscape of Indiana is fertile ground for the
Institute, and Lilly is proud to be a part of it." "The IBRI is an R&D model
that will help us address some of our most pressing medical needs. Despite
important advances in recent years, diseases such as diabetes continue to
affect our citizens at alarming rates. By pulling together the best minds for
collaborative thinking and research, the new institute will help move us
closer to solving some of the world's most difficult challenges in health and
nutrition," Dr. Lechleiter concluded. The Full Research Report on Eli Lilly &
Co. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/977d_LLY

--

GlaxoSmithKline plc (ADR) Research Report

On November 20, 2013, GlaxoSmithKline plc (ADR) (GSK) and Amicus Therapeutics
(Amicus) announced that Amicus has obtained global rights to develop and
commercialize the investigational pharmacological chaperone migalastat HCI as
a monotherapy and in combination with enzyme replacement therapy (ERT) for
Fabry. GSK reported that key highlights of the revised agreement include:
Amicus will have sole rights to the global drug development, regulatory and
commercial activities for the next-generation Fabry ERT (migalastat HCI
co-formulated with ERT) as well as migalastat HCI monotherapy; GSK will be
eligible for future regulatory and commercial milestone payments, as well as
royalty payments; and GSK will invest $3 million in Amicus through an equity
investment in a concurrent private placement in public equity (PIPE)
transaction. The Full Research Report on GlaxoSmithKline plc (ADR) - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/2a35_GSK

--

Sanofi SA (ADR) Research Report

On November 18, 2013, Sanofi SA (ADR) (Sanofi) announced the Company's
decision to stop all clinical trials and cancel plans for regulatory filings
with its investigational JAK2 inhibitor, fedratinib (SAR302503). The Company
reported that after a thorough risk-benefit analysis, including consultation
with the U.S. Food and Drug Administration (FDA), study investigators,
independent expert neurologists and neuro-radiologists, the Company determined
that the risk to patient safety outweighed the benefit that fedratinib bring
to patients. Sanofi informed that the decision follows reports of cases
consistent with Wernicke's encephalopathy in patients participating in
fedratinib clinical trials. The Full Research Report on Sanofi SA (ADR) -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/29ea_SNY

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.